You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
山東新華製藥股份(00719.HK)中期淨利升15.56%至1.72億元
格隆匯 08-21 16:41

格隆匯 8 月 21日丨山東新華製藥股份(00719.HK)公佈,截至2020年6月30日止6個月,公司營業收入為人民幣32.86億元,同比增長2.55%;歸屬於上市公司股東的淨利潤為人民幣1.72億元,同比增長15.56%;歸屬於上市公司股東的扣除非經常損益的淨利潤為人民幣1.54億元,同比增長12.23%;基本每股收益為人民幣0.28元。

積極應對全球經濟和外貿形勢急劇變化,上半年實現出口創匯1.74億美元,同比增長11.89%,外貿出口實現逆勢增長。

搶抓國內原料藥市場機遇,在抓好重點產品和特色原料藥銷售基礎上,積極擴大獸藥市場開拓,上半年原料藥內銷實現銷售收入人民幣3.93億元,同比增長11.88%。

整合各種渠道資源,加大線上服務力度,大力發展跨境出口業務,電商業務上半年實現銷售收入人民幣1.40億元,同比增長90.81%。

積極參與國家帶量採購及各地方招標,為大製劑戰略推進築基礎。上半年十大製劑戰略品種銷售6.36億片支,實現銷售收入人民幣2.48億元,同比分別增長34.4%、8.37%,市場佔有率進一步提高。

持續加大研發投入,上半年公司研發投入同比增長24.60%。公司解熱鎮痛藥物先進製造工程研究中心被認定為山東省工程研究中心。

上半年依達拉奉原料藥獲得上市資格,依達拉奉注射液獲得國家藥品監督管理局藥品註冊批件。頭孢氨苄膠囊、布洛芬片、克拉黴素片3個產品5個規格通過了仿製藥質量和療效一致性評價。

一批重點自動化、智能化項目正在紮實推進。二分廠綜合動力智能化項目進入設備安裝階段。4個自動控制重點項目如期施工。設備全生命管理系統進入現場檢測安裝。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account